HUADONG MEDICINE unveils promising diabetes treatment in early trials

HUADONG MEDICINE, a pharmaceutical company based in Hangzhou, China, has recently shared promising findings from the early stages of clinical trials for their new oral medication, HDM1002. Developed by their subsidiary Zhongmei HuaDong Pharmaceutical CO. LTD, HDM1002 is a GLP-1 receptor agonist designed to help manage diabetes and support weight loss.

The initial trials for HDM1002 consisted of two phases. In Phase Ia, the focus was on evaluating the drug's safety, tolerability, and how the body processes it in healthy adult volunteers. Results revealed that HDM1002 displayed consistent pharmacokinetics across different doses, with no significant negative effects reported. Notably, the drug demonstrated a dose-dependent decrease in post-meal blood sugar levels, regardless of the meal's content.

Subsequently, in Phase Ib, which involved overweight and obese participants, HDM1002 exhibited encouraging safety and tolerability profiles over a 28-day period. Individuals who received higher doses of the medication experienced significant weight loss, with an average reduction ranging from 4.9% to 6.8% from their initial weight. The most common side effects noted were mild gastrointestinal issues such as nausea and vomiting.

HDM1002, a unique formulation from Zhongmei HuaDong, has shown strong activation of the GLP-1 receptor in preclinical studies, leading to enhanced glucose control, decreased blood sugar levels, and notable weight loss benefits. The drug has already obtained regulatory approvals for treating diabetes in China and the US, as well as for weight management in China. Successful completion of Phase II trials in China sets the stage for further advancements and assessments of this innovative treatment.

The progress made by HUADONG MEDICINE with HDM1002 marks a significant step forward in the development of effective therapies for diabetes and weight management. With promising results from early clinical trials and regulatory approvals in key markets, HDM1002 holds great potential to offer improved health outcomes for individuals struggling with these conditions.